BERKELEY, CA USA (UroToday) - 
In this presentation, Bryan Mehlhaff, MD, of the Oregon Urology Institute, discusses the treatment history of a 49-year-old prostate cancer patient from the time of diagnosis through 2012.
The case lecture presentation will take approximately 12 minutes to complete.
Related Presentations:
- The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer, by Charles J. Ryan, MD
- Maximum androgen blockade with abiraterone - Case Lecture Presentation, by Charles J. Ryan, MD
Learn More About mCRPC Treatment
- Successful treatment of advanced metastatic prostate cancer following chemotherapy based on molecular profiling, "Beyond the Abstract," by Charles E. Myers, MD
- Advances in the treatment of prostate cancer - dawn of a new era - Abstract
- Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases - Abstract
- Non-metastatic CRPC and asymptomatic metastatic CRPC: Which treatment for which patient? - Abstract